2025年7月3日,上市仅一周的玛仕度肽(商品名:信尔美®)在北京大学人民医院开出全国首张处方,国内数以亿计的超重和肥胖人群迎来了一个全新的治疗选择。 与依靠降糖切入市场的司美格鲁肽、替尔泊肽不同,玛仕度肽以减重作为首发适应症,在电商平台和社交媒体上热度空前。这激起了业界对中国减重类药物商业化前景的无限遐想,众多机构预测其峰值销售额有望突破50亿元。 回顾全球“减重革命”商业化成绩,司美格鲁肽和...
Source Link2025年7月3日,上市仅一周的玛仕度肽(商品名:信尔美®)在北京大学人民医院开出全国首张处方,国内数以亿计的超重和肥胖人群迎来了一个全新的治疗选择。 与依靠降糖切入市场的司美格鲁肽、替尔泊肽不同,玛仕度肽以减重作为首发适应症,在电商平台和社交媒体上热度空前。这激起了业界对中国减重类药物商业化前景的无限遐想,众多机构预测其峰值销售额有望突破50亿元。 回顾全球“减重革命”商业化成绩,司美格鲁肽和...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.